Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 8:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Maridebart cafraglutide Clear all
Completed Phase 1 Interventional

Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations

NCT07226778
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Maridebart Cafraglutide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Anaheim, California • Daytona Beach, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

NCT06858839
View directory record Official record
Conditions
Obesity
Interventions
Maridebart Cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
3,853 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
74
States / cities
Anniston, Alabama • Daphne, Alabama • Mobile, Alabama + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 8, 2026, 8:38 AM EDT
Active, not recruiting Phase 1 Interventional

Effect of Maridebart Cafraglutide on the Heart's Electrical Activity

NCT07229157
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Maridebart Cafraglutide, Moxifloxacin, Placebo for Maridebart Cafraglutide, Placebo for Moxifloxacin
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Recruiting Phase 3 Interventional

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

NCT07575399
View directory record Official record
Conditions
Obesity or Overweight
Interventions
Maridebart Cafraglutide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
44
States / cities
Pelham, Alabama • Chandler, Arizona • Sun City, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Recruiting Phase 2 Interventional

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

NCT07441252
View directory record Official record
Conditions
Overweight or Obesity and Elevated Liver Fat
Interventions
Maridebart cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus

NCT07160257
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Maridebart cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Recruiting Phase 3 Interventional

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

NCT07037433
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Overweight, Obesity
Interventions
Maridebart Cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
45 Years to 99 Years
Enrollment
12,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
140
States / cities
Daphne, Alabama • Fairhope, Alabama • Huntsville, Alabama + 117 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

NCT06858878
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Interventions
Maridebart cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
59
States / cities
Mobile, Alabama • Gilbert, Arizona • Mesa, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Sep 8, 2026, 8:38 AM EDT
Recruiting Phase 3 Interventional

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

NCT07684144
View directory record Official record
Conditions
Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions
Maridebart Cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
27
States / cities
Gilbert, Arizona • Canoga Park, California • Cerritos, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 1 Interventional

A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations

NCT07313761
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Maridebart Cafraglutide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Anaheim, California • Los Alamitos, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 1 Interventional

The Effect of AMG 133 on Gastric Emptying

NCT07429032
View directory record Official record
Conditions
Overweight or Obesity
Interventions
AMG 133, Placebo, Acetaminophen
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 2 Interventional

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

NCT05669599
View directory record Official record
Conditions
Obesity, Overweight, Type 2 Diabetes Mellitus
Interventions
Maridebart Cafraglutide, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
29
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Recruiting Phase 3 Interventional

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

NCT07037459
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
Interventions
Maridebart cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
5,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
111
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 1 Interventional Results available

Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity

NCT04478708
View directory record Official record
Conditions
Obesity
Interventions
maridebart cafraglutide, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Anaheim, California • Tustin, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity

NCT06976372
View directory record Official record
Conditions
Overweight, Obesity
Interventions
AMG 133
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Anaheim, California • Los Alamitos, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 8, 2026, 8:38 AM EDT
Recruiting Phase 3 Interventional

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

NCT07684235
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Maridebart cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
70
States / cities
Anniston, Alabama • Daphne, Alabama • Mobile, Alabama + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants

NCT05056246
View directory record Official record
Conditions
Healthy Participants
Interventions
AMG 133
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity

NCT07717814
View directory record Official record
Conditions
Overweight and Obesity
Interventions
AMG 133 (frozen liquid), AMG 133 (liquid)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Anaheim, California • Daytona Beach, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Recruiting Phase 3 Interventional

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

NCT07225686
View directory record Official record
Conditions
Obesity, Obstructive Sleep Apnea
Interventions
Maridebart cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Northridge, California • Rolling Hills Estates, California • Brandon, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

NCT06660173
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Maridebart Cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
28
States / cities
Birmingham, Alabama • Anaheim, California • Canoga Park, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 8, 2026, 8:38 AM EDT
Active, not recruiting Phase 1 Interventional

Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity

NCT07523711
View directory record Official record
Conditions
Overweight, Obesity
Interventions
COC, Maridebart Cafraglutide
Drug
Lead sponsor
Amgen
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body

NCT07429045
View directory record Official record
Conditions
Overweight and Obesity
Interventions
AMG 133
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
5
States / cities
Lake Forest, California • Miami, Florida • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Recruiting Phase 3 Interventional

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

NCT07226765
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Maridebart cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Northridge, California • Rolling Hills Estates, California • Brandon, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 8, 2026, 8:38 AM EDT